Jan. 8 at 10:22 PM
$SRRK i didnt buy at 30$🙉
my personal opinion, without hate…
The competition is already running studies with approved medications. In the new studies, the dosage is being increased by a factor of x50.(yearly)
$SRRK needs to accelerate significantly. I am closely monitoring this company, but the situation is becoming challenging. For example, in my country, if there are multiple medications available for the same disease, only the cheapest one is reimbursed.
At this point, I still have the assessment from physicians in my country that this medication does not provide any additional positive benefit compared to the existing drugs on the market. This view is unanimous. It has also been documented in writing and published with all doctors here.
One possible reason is, that there is still insufficient data available. Based on the current state of knowledge, I was personally advised not to take this medication.
